Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Day One Biopharmaceuticals ( (DAWN) ) just unveiled an announcement.
Day One Biopharmaceuticals announced preliminary results for 2024, reporting approximately $57.2 million in net product revenue from OJEMDA, which received FDA accelerated approval. The company ended 2024 with around $531.7 million in cash and investments. In 2025, Day One plans to grow OJEMDA revenue, progress clinical trials for tovorafenib and DAY301, and maintain a strong financial position. The company also entered an exclusive licensing agreement with Ipsen for tovorafenib commercialization outside the U.S.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for both children and adults with life-threatening diseases. The company aims to address the lack of new therapies for pediatric cancer with a strategy to find, acquire, and develop first- or best-in-class medicines. Their pipeline includes tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program.
YTD Price Performance: -7.16%
Average Trading Volume: 1,053,576
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.19B
Learn more about DAWN stock on TipRanks’ Stock Analysis page.
